

**Confidently recommend an appropriate PARP inhibitor with industry leading BRCA variant classification**

**Precise™ Oncology Solutions includes two FDA-approved tests that can help clarify treatment options**

## BRACAnalysis CDx®

Germline Companion Diagnostic Test



**1 in 10** pancreatic<sup>1</sup>



**1 in 8** breast<sup>2</sup>



**1 in 6** prostate<sup>3</sup>



**1 in 4** ovarian<sup>4</sup>

Cancer patients have a **germline** mutation which may benefit from a targeted therapy.


Germline *BRCA1/2* status is a critical biomarker to help you determine treatment eligibility for your patients with breast, ovarian, pancreatic or prostate cancer.

BRACAnalysis CDx is an FDA-approved test to quickly provide accurate germline *BRCA1/2* reports so you can confidently recommend an appropriate PARP inhibitor without delay.

## MyChoice® CDx

Myriad HRD Companion Diagnostic Test


**Measure HRD status in patients with ovarian cancer**



MyChoice CDx examines ovarian cancer tumors using two individual methods (*BRCA1/2* mutation and genomic instability) to determine a patient's HRD status.

Studies show that by using these methods, MyChoice CDx can identify **34% more tumors** with HRD than other testing methods that use %LOH alone.<sup>5</sup>

**MyChoice CDx and BRACAnalysis CDx are the only commercially available and FDA-approved companion diagnostic tests that detect large rearrangements in the *BRCA* genes, accounting for up to 10% of variants in the associated cancer types<sup>6,7</sup>**



## The importance of variant classification

**43-63% of gBRCA mutations identified as a VUS at competing labs can be definitively classified using Myriad's variant classification program<sup>8</sup>**

Myriad Genetic Laboratories has over 25 years of experience in variant classification and reclassification of *BRCA1/2*. The resulting analysis and interpretation of the variants reduces the VUS rate in genetic test results and provides confidence for oncologists when determining the appropriate therapy for their patients.

## With focused results, you'll be able to create action from answers



It's simple and convenient to order germline and somatic tests at the same time



Make treatment decisions with confidence knowing that you're using a lab with proven standards and accuracy



An online portal will keep your patient's results in one location with a simple to read summary page that captures both germline and somatic information

### Experience Precise Oncology Solutions and turn complexity into clarity.

1. Tersmette AC, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res. 2001 Mar;7(3):738-744.

2. Foulkes WD et al. N Engl J Med. 2008; 359:2143-2153.

3. Nicolosi P, et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 2019 Apr 1;5(4):523-528.

4. Walsh T, et al. Proc Natl Acad Sci USA. 2011; 108(44): 18032-18037.

5. Mills et al. Presentation for 2020 SGO Annual Meeting. SGO Annual Meeting on Women's Cancer (Abstract 1)

6. Judkins T, et al. Wiley-Blackwell Online. 2012; 118(21):5210-5216

7. 3% of this tumor type is missed by Foundation Medicine, [https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne\\_CDx\\_Label\\_Technical\\_Info.pdf](https://info.foundationmedicine.com/hubfs/FMI%20Labels/FoundationOne_CDx_Label_Technical_Info.pdf)

8. Gradishar W, et al. Clinical variant classification: a comparison of public databases and a commercial testing laboratory. Oncologist. 2017;22(7):797-803.